1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Methylprednisolone Sodium Succinate for Injection, USP
Trade Name: Solu-Medrol; Solu-Medrone; Solu-Moderin
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as anti-inflammatory

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1A
Specific target organ systemic toxicity (repeated exposure): Category 2

US OSHA Specific - Classification

Physical Hazard: Combustible Dust

Label Elements

Signal Word: Danger
Hazard Statements:
H373 - May cause damage to organs through prolonged or repeated exposure
H360D - May damage the unborn child
May form combustible dust concentrations in air

Precautionary Statements:
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P314 - Get medical attention/advice if you feel unwell
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations
Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzyl Alcohol</td>
<td>100-51-6</td>
<td>202-859-9</td>
<td>Acute Tox.4 (H302)</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Acute Tox.4 (H332)</td>
<td></td>
</tr>
<tr>
<td>Methylprednisolone Sodium Succinate</td>
<td>2375-03-3</td>
<td>219-156-8</td>
<td>Repr. 1A (H360D)</td>
<td>67-87</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>STOT RE 2 (H373)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium phosphate, monobasic</td>
<td>7558-80-7</td>
<td>231-449-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium phosphate, dibasic</td>
<td>7558-79-4</td>
<td>231-448-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Lactose</td>
<td>63-42-3</td>
<td>200-559-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Description of First Aid Measures**

**Eye Contact:**
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:**
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:**
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed
Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, see Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed
Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Minimize dust generation and accumulation. Avoid contact with eyes, skin and clothing. Avoid breathing dust. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

#### Benzyl Alcohol

<table>
<thead>
<tr>
<th>Country</th>
<th>Limit (mg/m³)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bulgaria OEL - TWA</td>
<td>5.0</td>
</tr>
<tr>
<td>Czech Republic OEL - TWA</td>
<td>40</td>
</tr>
<tr>
<td>Finland OEL - TWA</td>
<td>10</td>
</tr>
<tr>
<td>Latvia OEL - TWA</td>
<td>5</td>
</tr>
<tr>
<td>Lithuania OEL - TWA</td>
<td>45</td>
</tr>
<tr>
<td>Poland OEL - TWA</td>
<td>240</td>
</tr>
</tbody>
</table>

#### Methylprednisolone Sodium Succinate

<table>
<thead>
<tr>
<th>Country</th>
<th>Limit (mg/m³)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer OEL TWA-8 Hr</td>
<td>4 µg</td>
</tr>
</tbody>
</table>

**Exposure Controls**

- **Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

- **Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

- **Hands:** Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

- **Eyes:** Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

- **Skin:** Wear impervious protective clothing to prevent skin contact – consider use of disposable clothing where appropriate. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

- **Respiratory protection:** Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical State</td>
<td>Powder</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available</td>
</tr>
<tr>
<td>Molecular Formula</td>
<td>Mixture</td>
</tr>
<tr>
<td>Color</td>
<td>White</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

| Solvent Solubility              | Soluble: Alcohols      |
| Water Solubility                | No data available      |
| Solubility                      | Soluble: Water         |
| pH                              | No data available      |
| Melting/Freezing Point (°C)     | No data available      |
| Boiling Point (°C)              | No data available      |

**Partition Coefficient: (Method, pH, Endpoint, Value)**

- Sodium phosphate, dibasic
  - No data available
9. PHYSICAL AND CHEMICAL PROPERTIES

Sodium phosphate, monobasic
No data available

Lactose
No data available

Methylprednisolone Sodium Succinate
No data available

Methylprednisolone
Predicted 7.4 Log D 1.99

Benzy1 Alcohol
No data available

Decomposition Temperature (°C): No data available

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions
Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of various forms of the active ingredients. The remaining information describes the potential hazards of the individual ingredients.

Short Term: May cause eye irritation (based on components). May be harmful if absorbed through the skin.

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs.

Known Clinical Effects: Adverse clinical reactions include the development of hypersensitivity and/or irritation leading to rashes, itching, and burning. Clinical use has resulted in hormonal alterations. Drugs of this class may cause Cushing's syndrome, manifested by moon face, obesity, headache, acne, thirst, increased urination, impotence, menstrual irregularities, facial hair growth, and mental changes.

Acute Toxicity: (Species, Route, End Point, Dose)
### 11. TOXICOLOGICAL INFORMATION

**Methylprednisolone Sodium Succinate**

<table>
<thead>
<tr>
<th>Species</th>
<th>Route</th>
<th>LD 50</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td>&gt; 5000 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>Para-periosteal</td>
<td>LD 50</td>
<td>718 mg/kg</td>
</tr>
<tr>
<td>Mouse</td>
<td>Intravenous</td>
<td>LD 50</td>
<td>953 mg/kg</td>
</tr>
<tr>
<td>Rat</td>
<td>Intraperitoneal</td>
<td>LD 50</td>
<td>512 mg/kg</td>
</tr>
<tr>
<td>Mouse</td>
<td>Intraperitoneal</td>
<td>LD 50</td>
<td>902 mg/kg</td>
</tr>
</tbody>
</table>

**Methylprednisolone**

<table>
<thead>
<tr>
<th>Species</th>
<th>Route</th>
<th>LD 50</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td>&gt; 2000 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Mouse</td>
<td>Oral</td>
<td>450 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>Intraperitoneal</td>
<td>LD 50</td>
<td>1000 mg/kg</td>
</tr>
<tr>
<td>Mouse</td>
<td>Intraperitoneal</td>
<td>LD 50</td>
<td>1409 mg/kg</td>
</tr>
<tr>
<td>Rat</td>
<td>Subcutaneous</td>
<td>LD 50</td>
<td>&gt;3000 mg/kg</td>
</tr>
</tbody>
</table>

**Benzyl Alcohol**

<table>
<thead>
<tr>
<th>Species</th>
<th>Route</th>
<th>LC 50</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td>1230 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>Para-periosteal</td>
<td>LD 50</td>
<td>53 mg/kg</td>
</tr>
<tr>
<td>Rat</td>
<td>Inhalation</td>
<td>LC50</td>
<td>&gt;4.178 mg/L</td>
</tr>
</tbody>
</table>

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

**Irritation / Sensitization: (Study Type, Species, Severity)**

**Methylprednisolone**

<table>
<thead>
<tr>
<th>Route</th>
<th>Species</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Rabbit</td>
<td>No effect</td>
</tr>
<tr>
<td>Eye</td>
<td>Rabbit</td>
<td>No effect</td>
</tr>
<tr>
<td>Skin Sensitization - GPMT</td>
<td>Guinea Pig</td>
<td>No effect</td>
</tr>
</tbody>
</table>

**Benzyl Alcohol**

<table>
<thead>
<tr>
<th>Route</th>
<th>Species</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye</td>
<td>Rabbit</td>
<td>Severe</td>
</tr>
<tr>
<td>Skin</td>
<td>Rabbit</td>
<td>Minimal</td>
</tr>
<tr>
<td>Skin</td>
<td>Guinea Pig</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

**Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

**Methylprednisolone**

<table>
<thead>
<tr>
<th>Duration</th>
<th>Species</th>
<th>Route</th>
<th>LD 50</th>
<th>Effect</th>
<th>Target Organ</th>
</tr>
</thead>
<tbody>
<tr>
<td>42 Day(s)</td>
<td>Dog</td>
<td>Oral</td>
<td>167 µg/kg/day</td>
<td>LOAEL</td>
<td>Adrenal gland</td>
</tr>
<tr>
<td>6 Week(s)</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>500 µg/kg/day</td>
<td>LOAEL</td>
<td>None identified</td>
</tr>
<tr>
<td>14 Week(s)</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>0.4 µg/kg/day</td>
<td>NOAEL</td>
<td>Blood forming organs, Adrenal gland</td>
</tr>
<tr>
<td>52 Week(s)</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>4 µg/kg/day</td>
<td>NOAEL</td>
<td>Blood forming organs, Adrenal gland</td>
</tr>
</tbody>
</table>

**Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))**

**Methylprednisolone Sodium Succinate**

<table>
<thead>
<tr>
<th>Route</th>
<th>Species</th>
<th>Dose</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcutaneous</td>
<td>Rat</td>
<td>40 mg/kg/day</td>
<td>LOAEL</td>
</tr>
<tr>
<td>Subcutaneous</td>
<td>Rat</td>
<td>40 mg/kg/day</td>
<td>LOAEL</td>
</tr>
</tbody>
</table>

**Methylprednisolone**

---

METHYLPPREDNISOLONE SODIUM SUCCINATE FOR INJECTION
11. TOXICOLOGICAL INFORMATION

Reproductive & Fertility
- Rat: Subcutaneous, 0.004 mg/kg/day, NOAEL, Paternal toxicity
- Rat: Subcutaneous, 0.02 mg/kg/day, LOAEL, Fetotoxicity

Embryo / Fetal Development
- Rat: Subcutaneous, 1.0 mg/kg/day, LOAEL, Fetotoxicity, Teratogenic
- Mouse: Intramuscular, 330 mg/kg/day, LOAEL, Teratogenic
- Rabbit: Intramuscular, 0.1 mg/kg/day, LOAEL, Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

- Methylprednisolone Sodium Succinate
  - Direct DNA Interaction: Not applicable, Negative
  - In Vitro Cytogenetics: Not applicable, Negative

- Methylprednisolone
  - Bacterial Mutagenicity (Ames): Salmonella, Negative
  - Unscheduled DNA Synthesis: Rat Hepatocyte, Negative
  - Mammalian Cell Mutagenicity: Chinese Hamster Ovary (CHO) cells, Negative
  - Direct DNA Interaction: Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

- Benzyl Alcohol
  - Pimephales promelas (Fathead Minnow): EPA LC50, 96 Hours, 460 mg/L
  - Daphnia magna (Water Flea): OECD EC50, 48 Hours, 230 mg/L
  - Pseudokirchneriella subcapitata (Green Alga): OECD EC50, 72 Hours, 500 mg/L

- Benzyl Alcohol
  - Daphnia magna (Water Flea): OECD 21 Day(s), EC50, 66 mg/L, Reproduction

Persistence and Degradability:

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

- Benzyl Alcohol
  - OECD: Activated sludge, Ready, 92% After 14 Day(s), Ready

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

- Methylprednisolone
  - Predicted, 7.4, Log D, 1.99

Mobility in Soil: No data available
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Benzyl Alcohol
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 202-859-9

Sodium phosphate, monobasic
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 231-449-2

Sodium phosphate, dibasic
- CERCLA/SARA 313 Emission reporting: Not Listed
- CERCLA/SARA Hazardous Substances and their Reportable Quantities: 5000 lb, 2270 kg
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 231-448-7

Lactose
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>REACH - Annex IV - Exemptions from the obligations of Register:</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>200-559-2</td>
</tr>
</tbody>
</table>

Methylprednisolone Sodium Succinate

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>219-156-8</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

- Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
- Acute toxicity, inhalation-Cat.4; H332 - Harmful if inhaled
- Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure
- Reproductive toxicity-Cat.1A; H360D - May damage the unborn child

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection.

Revision date: 27-Oct-2016

Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.